Objectives: To evaluate the efficacy and safety of bevacizumab plus chemotherapy in the treatment of patients with metastatic colorectal cancer
Methods: In the single-center, retrospective observational study. We collected data from medical records and electronic databases in patients with metastatic colorectal cancer who received bevacizumab plus chemotherapy during 1 October 2010 to 31 March 2017. Outcome analyses were 1) median-overall survival (OS), progression-free survival (PFS), response rate (RR) and 2) toxicity.
Results: From a total of 37 patients. Thirty-five patients are retrieved for efficacy analysis and found that bevacizumab plus chemotherapy showed OS 18.26 months (95%CI 14.25-22.27), PFS 10.17 months (95%CI 8.23-10) and RR: partial response 54.28% and progressive disease 34.29%. All patients are retrieved for safety analysis. Hematologic toxicities were anemia 81.08%, thrombocytopenia 40.54%and neutropenia 32.43%. Non-hematologic toxicities were peripheral neuropathy 70.27%, oral mucositis 48.65% and fatigue 43.24%. Common toxicities associated with bevacizumab were proteinuria (21.62%) and 1 patient discontinued bevacizumab because she had a stroke.
Conclusions: From this study, bevacizumab plus chemotherapy showed efficacy including OS 18.26 months, PFS 10.17 months and overall response rate 54.28%. The common hematologic toxicity of bevacizumab plus chemotherapy were anemia, thrombocytopenia and neutropenia and non hematologic toxicity were neuropathy, oral mucositis and fatigue.